November 2024 - Page 3 of 13

Dr. Kan Gong: Reflecting on Key Challenges and Hotspots in Renal Cancer Diagnosis and Treatment in China, Exploring New Frontiers in Translational Research | The 8th West China Uro-Oncology Tianfu Academic Conference

By Peng Longmei 2024.11.25

Renal cancer is one of the three major malignancies in the urinary system. Early-stage renal cancer often presents with concealed symptoms, making it difficult to differentiate between benign and malignant tumors. Advanced renal cancer primarily relies on targeted or immunotherapy, yet the effectiveness of existing targeted drugs is low, and resistance tends to develop easily. Therefore, conducting targeted translational research based on clinical problems offers hope for improving the current state of renal cancer diagnosis and treatment in China. At the 8th West China Uro-Oncology Tianfu Academic Conference held in Chengdu, Oncology Frontier invited Dr. Kan Gong from the Institute of Urology at Peking University and the Department of Urology at Peking University First Hospital to share insights into the current state of renal cancer diagnosis and treatment in China, as well as the highlights of his team’s work in translational research.

Ten Years of Progress in Standardization: Key Updates to the 2024 Chinese Guidelines for Advanced Breast Cancer Treatment

By Lisa Cui 2024.11.25

At the 2024 Breast Cancer Standardized Diagnosis and Treatment & Quality Control Conference (November 8–10, Beijing), Dr. Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences, presented the key updates to the 2024 Chinese Advanced Breast Cancer Clinical Guidelines (ABCC). The updated ABCC guidelines include treatment recommendations for different breast cancer subtypes and introduce a new chapter on managing adverse events. Below is a summary of the key updates to the guidelines.

Strengthening Global Bonds in Cancer Control: Highlights from the CACA-SLACOM and CACA-SIS Summits

By Mourabit Halima 2024.11.25

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Summit (AOS), hosted by the Chinese Anti-Cancer Association (CACA) in collaboration with the Chinese Academy of Integrative Medicine and the Shaanxi Anti-Cancer Association, took place from November 14–17 in the ancient city of Xi'an. This prestigious event featured specialized summits co-organized by CACA and global cancer organizations, including the National Comprehensive Cancer Network (NCCN), Union for International Cancer Control (UICC), Society of Latin American and Caribbean Oncology (SLACOM), and International Society of Breast Disease (SIS), to foster international collaboration in cancer prevention and treatment.

CSCO 2024丨Dr. Wenhua Liang: Collaborative Efforts — Exploring New Precision Medicine Pathways for NSCLC in the Era of Immunotherapy

By Yin, Jiale 2024.11.24

The 27th National Conference of Clinical Oncology and 2024 CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen from September 25 to 29, 2024. The conference included multiple sessions on lung cancer, which brought together the latest advances and frontiers in lung cancer research from both domestic and international perspectives. During the conference, Oncology Frontier invited Dr. Wenhua Liang from The First Affiliated Hospital of Guangzhou Medical University to share new clinical developments in immunotherapy combinations for non-small cell lung cancer (NSCLC) and recent breakthroughs in precision diagnostic pathways.

ESMO 2024丨Unveiling the “Genetic Map” of Pancreatic Cancer: How Driver Mutations Guide Personalized Treatment

By Yin, Jiale 2024.11.24

At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, in the session dedicated to basic science and translational research, researchers presented groundbreaking findings on driver mutations in pancreatic cancer and their role in predicting patient prognosis and treatment response. The research highlighted significant differences in the diversity of driver gene mutations between healthy pancreatic tissue and tumor tissue, suggesting these differences play a crucial role in the formation and progression of pancreatic cancer. These findings also provide an important basis for personalized treatment. Dr. Francisco Martínez-Jiménez from Vall d'Hebron Barcelona Hospital Campus , Spain, interpreted the main research findings and discussed their clinical implications.

ESMO 2024丨Dr. Antonio Passaro: Zipalertinib Shows Promising Efficacy and Safety in EGFR Exon 20 Insertion-Mutant NSCLC Patients

By Mourabit Halima 2024.11.24

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain, where several significant advances in lung cancer research were presented. Dr. Antonio Passaro from the European Institute of Oncology Division of Thoracic Oncology in Milan, Italy, shared insights on the safety and antitumor activity of Zipalertinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations. Oncology Frontier had the opportunity to interview Professor Passaro on-site, where he discussed the latest advances in EGFR-targeted therapies.

Prof. Lin Zhang: Precision Surgery Empowers Y-90 Therapy

By El Bachir MOURABIT 2024.11.24

The field of cancer treatment has made substantial progress, entering an era of multi-faceted, comprehensive approaches. With the government’s focus on major diseases, traditional cancer treatments like surgery, interventional therapy, radiotherapy, and chemotherapy have evolved into multidisciplinary approaches. Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) is now emerging as a key treatment option for liver cancer. On October 12, the Radiotherapy and Immuno-Oncology Symposium successfully took place. Oncology Frontier invited Prof. Lin Zhang, the first certified Y-90 supervisor in mainland China and an expert from Beijing Tsinghua Changgung Hospital, to discuss the clinical applications and precision surgical principles guiding Y-90 therapy.

SITC 2024丨First-Line Dostarlimab Plus Chemotherapy Shows Overall Survival Advantage in Advanced NSCLC

By Mourabit Halima 2024.11.23

The PERLA trial results demonstrated that Dostarlimab plus chemotherapy achieved better overall survival (OS) compared to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer (NSCLC), with a median OS of 20.2 months vs. 15.9 months.

WCLC 2024丨Dr. Mark G. Kris: New Standards in Treating Resectable NSCLC—Perioperative vs. Neoadjuvant Therapy?

By El Bachir MOURABIT 2024.11.23

The treatment of resectable non-small cell lung cancer (NSCLC) continues to evolve, with debates focusing on whether patients should receive adjuvant immunotherapy following successful neoadjuvant immunotherapy and surgery. This topic was a highlight of discussions at the 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC). Dr. Mark G. Kris from Memorial Sloan Kettering Cancer Center shared his insights on this matter.

Dr. Jin Yang: Advancing Quality Control in Breast Cancer Care—Insights into National Performance Indicators and Challenges

By Mourabit Halima 2024.11.22

Editorial Note: Quality control has become an increasingly critical focus in breast cancer diagnosis and treatment. As China enhances its cancer prevention and control framework, the standardization of breast cancer care is receiving growing attention. At the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Dr. Jin Yang from The First Affiliated Hospital Xi'an Jiao Tong University presented a comprehensive report titled Quality Control in Breast Cancer Care and National Performance Indicators. In an exclusive interview with Oncology Frontier, Professor Yang provided in-depth insights into the content, significance, and implementation challenges of these quality control measures, illuminating the path forward for breast cancer diagnosis and treatment in China.